Biopharmaceutical company developing therapies for the treatment of anemia, fibrotic diseases, and cancer.
FibroGen, Inc. is a pioneering biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies aimed at addressing significant unmet medical needs. Central to its portfolio is Roxadustat, an oral small molecule inhibitor targeting hypoxia inducible factor prolyl hydroxylases. This compound has completed Phase III clinical trials in the United States, Europe, China, and Japan for treating anemia associated with chronic kidney disease. Additionally, Roxadustat is in Phase II/III development in China for anemia linked to myelodysplastic syndromes.
Another key asset in FibroGen's pipeline is Pamrevlumab, a human monoclonal antibody designed to inhibit connective tissue growth factor. Pamrevlumab is advancing through Phase III clinical trials for multiple indications, including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy. These programs underscore FibroGen's commitment to advancing treatments across a spectrum of severe and complex medical conditions.
Founded in 1993 and headquartered in San Francisco, California, FibroGen, Inc. operates with strategic collaborations that amplify its research and development efforts. Collaborative agreements with Astellas Pharma Inc. and AstraZeneca AB enhance FibroGen's capabilities in advancing its pipeline and exploring novel therapeutic approaches. The company's robust scientific foundation and partnerships position it at the forefront of biopharmaceutical innovation, poised to deliver transformative therapies to patients worldwide.
FibroGen continues to leverage its expertise in biology and drug development to expand its pipeline and address critical medical needs. With a focus on precision medicine and targeted therapies, FibroGen aims to make substantial advancements in treating diseases where current treatment options are limited or inadequate.